Explore more publications!
Tonga Healthcare Daily
Submit Press Release

Tonga Healthcare Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tonga Healthcare Daily.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on November 7, 2025

Spyre Therapeutics Announces Grants of Inducement Awards
November 7, 2025

Spyre Therapeutics Announces Grants of Inducement Awards

Indeterminate GlobeNewswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 7, 2025

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update
November 7, 2025

Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update

Indeterminate GlobeNewswire
Nanox to Report Third Quarter 2025 Financial Results on November 20, 2025
November 7, 2025

Nanox to Report Third Quarter 2025 Financial Results on November 20, 2025

Indeterminate GlobeNewswire
Arcadia Biosciences (RKDA) Announces Third Quarter 2025 Financial Results and Business Highlights
November 7, 2025

Arcadia Biosciences (RKDA) Announces Third Quarter 2025 Financial Results and Business Highlights

Indeterminate GlobeNewswire
BillionToOne Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
November 7, 2025

BillionToOne Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Indeterminate GlobeNewswire
InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria
November 7, 2025

InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria

Indeterminate GlobeNewswire
Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
November 7, 2025

Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week

Indeterminate GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 7, 2025

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Exicure, Inc. Reports Third Quarter 2025 Financial Results
November 7, 2025

Exicure, Inc. Reports Third Quarter 2025 Financial Results

Indeterminate GlobeNewswire
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 7, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Maximus Announces First-Ever Topical Oxytocin Cream for Mood Enhancement and Sleep Support
November 7, 2025

Maximus Announces First-Ever Topical Oxytocin Cream for Mood Enhancement and Sleep Support

Indeterminate GlobeNewswire
All Smiles Dental Studio Launches Full Dental Implant Services and In-House Membership Plan to Support the Encinitas Community
November 7, 2025

All Smiles Dental Studio Launches Full Dental Implant Services and In-House Membership Plan to Support the Encinitas Community

Indeterminate GlobeNewswire
Protext Mobility, Inc. (OTC: TXTM) Announces Launch Phase of Its Next-Generation Investor Relations Suite and Corporate Website Modernization — Ushering in a New Era of Transparency, Innovation, and Shareholder Confidence
November 7, 2025

Protext Mobility, Inc. (OTC: TXTM) Announces Launch Phase of Its Next-Generation Investor Relations Suite and Corporate Website Modernization — Ushering in a New Era of Transparency, Innovation, and Shareholder Confidence

Indeterminate GlobeNewswire
PetVivo Sets Fiscal Second Quarter 2026 Conference Call for Friday, November 14, 2025 at 5:00 p.m. ET
November 7, 2025

PetVivo Sets Fiscal Second Quarter 2026 Conference Call for Friday, November 14, 2025 at 5:00 p.m. ET

Indeterminate GlobeNewswire
Neurocept Unveiled: Exploring the Science Behind This Neurocept Brain Support Supplement Transforms Cognitive Health and Memory Enhancement
November 7, 2025

Neurocept Unveiled: Exploring the Science Behind This Neurocept Brain Support Supplement Transforms Cognitive Health and Memory Enhancement

Indeterminate GlobeNewswire
Global Patient Monitoring Market to Reach $55.8 Billion by End of 2030
November 7, 2025

Global Patient Monitoring Market to Reach $55.8 Billion by End of 2030

Indeterminate GlobeNewswire
OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines
November 7, 2025

OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines

Indeterminate GlobeNewswire
Présentation poster sur OSE-Cytomask®, une technologie innovante de « Cis-Démasquage » des cytokines visant à augmenter l’indice thérapeutique des immunocytokines
November 7, 2025

Présentation poster sur OSE-Cytomask®, une technologie innovante de « Cis-Démasquage » des cytokines visant à augmenter l’indice thérapeutique des immunocytokines

Indeterminate GlobeNewswire
Chemed Corporation Declares Quarterly Dividend of 60 Cents
November 7, 2025

Chemed Corporation Declares Quarterly Dividend of 60 Cents

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions